2010-01-27 16:28:03 -

Research and Markets ( www.researchandmarkets.com/research/68e976/analytical_tool : ) has announced the addition of the " Analytical Tool - Lung Cancer - 2010 : " report to their offering.

Analytical Tool - Lung Cancer is a premium combo product of "Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio Planning" and "Lung Cancer Drug Pipeline Update 2010."

According to market analytical studies, the therapeutic lung cancer drug market is predicted to exceed $4 billion between 2010 and 2015.

Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012: Aventis' Taxotere (docetaxel), Bristol-Myers Squibb's Paraplatin (carboplatin) and Eli Lilly's Gemzar (gemcitabine). The third-generation chemotherapeutic agents have expanded

the therapeutic options in the treatment of advanced lung cancer. However, despite their contributions, science has reached a therapeutic plateau. Indeed, both Avastin and Efaproxyn have generated exciting data.

This combo product assists in your strategic planning decisions in oncology drug development. Understand the clinical and strategic challenges towards the commercialization of drugs in lung cancer treatments. Assess opportunities and risks for the continued development of innovative developmental treatments.

Find out more about each product by clicking on respective links.

For more information visit www.researchandmarkets.com/research/68e976/analytical_tool :



Research and MarketsLaura Wood, Senior ManagerU.S. Fax:

646-607-1907Fax (outside U.S.): +353-1-481-1716 press@researchandmarkets.com : mailto:press@researchandmarkets.com